Loading...

← Back to Leaderboard

Mark Sculpher

Institution: Unknown

Primary Field: Health (weighted toward more recent publications)

Homepage: https://www.york.ac.uk/che/staff/research/mark-sculpher/

First Publication: 1995

Most Recent: 2024

RePEc ID: psc810 ↗

Publication Scores

Scores use coauthorship adjustment: α/n credit per paper, where n = number of authors. α = 2.02: calibrated so average adjusted count equals average raw count (a zero-sum adjustment).

Period S (4x) A (2x) B (1x) C (½x) Total Percentile
Last 5 Years 0.00 0.00 0.91 0.00 0.91 25%
Last 10 Years 0.00 0.00 2.93 0.00 2.93 55%
All Time 0.00 0.00 12.51 0.38 12.89 90%

Publication Statistics

Raw Publications 22
Coauthorship-Adjusted Count 13.27

Publications (22)

Year Article Journal Tier Authors
2024 Achieving dynamic efficiency in pharmaceutical innovation: Identifying the optimal share of value and payments required Health Economics B 5
2021 Estimating the shares of the value of branded pharmaceuticals accruing to manufacturers and to patients served by health systems Health Economics B 4
2020 Distributional cost effectiveness analysis of West Yorkshire low emission zone policies Health Economics B 3
2018 Social value and individual choice: The value of a choice‐based decision‐making process in a collectively funded health system Health Economics B 4
2018 How to design the cost‐effectiveness appraisal process of new healthcare technologies to maximise population health: A conceptual framework Health Economics B 4
2017 Characterising Uncertainty in the Assessment of Medical Devices and Determining Future Research Needs Health Economics B 6
2015 Causes for Concern: Is Nice Failing to Uphold Its Responsibilities to All Nhs Patients? Health Economics B 4
2011 Dangerous omissions: the consequences of ignoring decision uncertainty Health Economics B 4
2010 Sins of omission and obfuscation: IQWIG's guidelines on economic evaluation methods Health Economics B 2
2010 An economic model for the prevention of MRSA infections after surgery: non-glycopeptide or glycopeptide antibiotic prophylaxis? European Journal of Health Economics C 8
2006 Discounting and cost‐effectiveness in NICE – stepping back to sort out a confusion Health Economics B 8
2006 Whither trial‐based economic evaluation for health care decision making? Health Economics B 4
2006 Evidence synthesis, parameter correlation and probabilistic sensitivity analysis Health Economics B 3
2005 Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra Health Economics B 8
2005 Assessing generalisability by location in trial‐based cost‐effectiveness analysis: the use of multilevel models Health Economics B 4
2005 Estimating mean QALYs in trial‐based cost‐effectiveness analysis: the importance of controlling for baseline utility Health Economics B 3
2005 Estimating utility data from clinical indicators for patients with stable angina European Journal of Health Economics C 4
2002 Recognising diversity in public preferences: the use of preference sub‐groups in cost‐effectiveness analysis. Authors' reply Health Economics B 2
2001 Representing uncertainty: the role of cost‐effectiveness acceptability curves Health Economics B 3
2001 Recognizing diversity in public preferences: The use of preference sub‐groups in cost‐effectiveness analysis Health Economics B 2
1998 The cost‐effectiveness of preference‐based treatment allocation: the case of hysterectomy versus endometrial resection in the treatment of menorrhagia Health Economics B 1
1995 Sensitivity analysis in economic evaluation: A review of published studies Health Economics B 2